Suggested Learning

Update: Most antidepressants ineffective in young people

Antidepressants “do not seem to offer a clear advantage for children and adolescents”, according to the Lancet, while “robust evidence” suggests that venlafaxine increases suicidal behaviour or ideation.

The meta-analysis of 34 trials involved 5,260 participants (mean age 9-18 years) and 14 antidepressants, although the authors admit that most of the evidence was “very low” quality.

Only fluoxetine was significantly more effective than placebo (standardised mean difference -0.51). Fluoxetine was also better tolerated than duloxetine (odds ratio [OR] 0.31) and imipramine (OR 0.23). Patients taking imipramine (OR 5.49), venlafaxine (OR 3.19) and duloxetine (OR 2.80) had more discontinuations due to adverse events over eight weeks than with placebo.

The authors suggest that “fluoxetine should be considered the best available choice when a pharmacological treatment is indicated for moderate to severe depression in people younger than 18 years who do not have access to psychotherapy or have not responded to non-pharmacological interventions”.

Venlafaxine was associated with a 13 per cent increased risk of suicidal behaviour or ideation compared to placebo and a greater risk than escitalopram (16 per cent), imipramine (16 per cent), duloxetine (14 per cent), fluoxetine (15 per cent) and paroxetine (19 per cent).

The authors noted the lack of “reliable data on suicidality for many antidepressants” and emphasised the importance of closely monitoring children and adolescents, particularly when starting antidepressants.

(DOI:10.1016/S0140-6736(16) 30385-3)

Latest discussions

  1. Pre reg exams

    At present the students who graduated tw...

  2. Pre reg exams

This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Magazine's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.